Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ICP-192 in unresectable or metastatic urothelial carcinoma with specific FGFR genomic abnormalities
CTR20200688Phase 2Active
- Sponsor
- Beijing Tiancheng Pharmaceutical Technology
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gunagratinib in transitional cell carcinoma (TCC), sponsored by Beijing Tiancheng Pharmaceutical Technology. Started Jun 2020; status: active.
02
Drugs
gunagratinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20200688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200688.